Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavoglurant in Parkinson's Patients With Severe L-dopa Induced Dyskinesias
NCT00888004Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2009
- Primary completion
- Aug 2009
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dyskinesia comparing AFQ056 + L-dopa with Placebo + L-dopa (2 arms). Primary endpoints: modified Abnormal Involuntary Movement Scale at 20 days, Safety and Tolerability at 20 days and 1 more. Started Mar 2009; status: completed.
02
Drugs
mavoglurant
03
Conditions
dyskinesia
Beyond the preview
Go deeper on NCT00888004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00888004.